Form 6-K XORTX Therapeutics Inc. For: Jun 30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2026

Commission File Number: 001-40858

 

XORTX Therapeutics Inc.

3710 – 33^rd Street NW, Calgary, Alberta, T2L 2M1

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX THERAPEUTICS INC.
		(Registrant)
Date:	August 14, 2026	By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Co-Chief Executive Officer

 

 

EXHIBIT INDEX

 

99.1	Condensed Interim Consolidated Financial Statements for the six months ended June 30, 2026
99.2	Management Discussion and Analysis for the six months ended June 30, 2026
99.3	Co-CEO Certificate
99.4	Co-CEO Certificate
99.5	CFO Certificate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

EXHIBIT 99.3

EXHIBIT 99.4

EXHIBIT 99.5

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SurveillanceGrid’s Innovative Solutions Help Make Hollister Motorcycle Rally A Success
• DTF Printing Made Simple: From Printer to Finished Custom Apparel
• NOAA confirms hottest month on record across the contiguous U.S.